Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Treatment-resistant depression
Economic burden and healthcare resource utilization
16 evidence topics · 16 sources
National annual burden of TRD within medication-treated MDD in the United States
“The estimated 12-month prevalence of medication-treated MDD in the United States was 8.9 million adults, and 2.8 million (30.9%) had TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total annual burden of medication-treated MDD among the US population was $92.7 billion, with $43.8 billion (47.2%) attributable to TRD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The share of TRD was 56.6% ($25.8 billion) of the health care burden, 47.7% ($8.7 billion) of the unemployment burden, and 32.2% ($9.3 billion) of the productivity burden of medication-treated MDD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental societal economic burden of MDD in the United States in 2019
“In 2019, the number of adults with MDD in the USA was estimated at 19.8 million (62.7% female; 32.9% severe MDD), and the incremental societal economic burden of MDD was estimated at $333.7 billion ($382.4 billion in 2023 US dollars), or $16,854 per adult with MDD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary cost drivers were healthcare costs ($127.3 billion; 38.1%), household-related costs ($80.1 billion; 24.0%), presenteeism ($43.3 billion; 13.0%), and absenteeism ($38.4 billion; 11.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the simulated scenario, a hypothetical novel therapy with a 50.0% early response rate was associated with a 7.7% reduction in the economic burden of MDD relative to standard of care over 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercially insured adults: health care costs, work loss, and employment status change
“TRD patients (N = 6,411) had more HRU than either matched control cohort, translating into higher per patient per year (PPPY) health care costs: $6,709 and $9,917 more than non-TRD MDD and non-MDD patients, respectively (P < .001 for both).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TRD patients with work loss data (N = 1,908) had 35.8 work loss days PPPY (1.7 and 6.2 times the work loss rate in non-TRD MDD and non-MDD patients, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Work loss-related costs in TRD patients were $1,811 higher than non-TRD MDD and $3,460 higher than in non-MDD patients (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TRD patients had 1.3-1.4 times the rate of employment status change versus control cohorts (all P < .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commercially insured adults with physical conditions: resource use, health care costs, and work loss
“A total of 2,317 patients with TRD (mean age, 47.6 years; 63.1%, female; mean follow-up, 19.7 months) had ≥ 1 co-occurring key physical condition (cardiovascular, 52.5%; metabolic, 48.2%; respiratory, 16.4%; and cancer, 9.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relative to non-TRD MDD and non-MDD cohorts, respectively, patients with TRD had 46% and 235% more inpatient admissions, 28% and 128% more emergency department visits, and 53% and 155% more outpatient visits (all P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Health care costs were $22,541 in the TRD cohort, $17,450 in the non-TRD MDD cohort, and $10,047 in the non-MDD cohort, yielding cost differences of $5,091 (vs. non-TRD MDD) and $12,494 (vs. non-MDD; all P < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with work loss data available (n = 278/cohort), those with TRD had 2.0 and 2.9 times more work loss as well as $8,676 and $10,323 higher work loss costs relative to those with non-TRD MDD and without MDD, respectively (all P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Commercially insured employees: direct and indirect costs over 2 years
“Employees who initiated a third antidepressant following two antidepressant treatments of adequate dose and duration or who met published TRD criteria were classified as TRD likely (N = 2312).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Average direct 2-year costs were significantly higher for TRD-likely employees ($22,784) compared with MDD controls ($11,733), p < 0.0001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Average indirect costs were also higher among TRD-likely employees ($12,765) compared with MDD controls ($6885), p < 0.0001.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Commercially insured adults: episode duration and total costs of TRD episodes
“Of all episodes, 7% were TRD, with a mean duration of 571 (285) days vs. 200 (198) days for non-TRD MDD episodes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total all-cause costs were $19,626 ($44,160) for TRD and $7440 ($25,150) for non-TRD MDD episodes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare beneficiaries: resource use and health care costs
“Of these, 3,224 (10.9%) met the study definition of TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the observation period, the total all-cause PPPY healthcare costs were $25,059 in the TRD cohort, $19,945 in the non-TRD MDD cohort, and $14,410 in the non-MDD cohort (all P<0.001; Fig 3 and Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TRD cohort had significantly higher adjusted PPPY all-cause healthcare costs versus the non-TRD MDD (adjusted cost difference = $3,377, P<0.001) or non-MDD cohorts (adjusted cost difference = $3,675, P<0.001; Fig 3 and Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TRD cohort had higher rates of PPPY behavioral health-related HRU relative to the non-TRD MDD cohort (e.g., inpatient visits: IRR = 1.49) and versus the non-MDD cohort (e.g., inpatient visits: IRR = 3.84, all P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare beneficiaries: published correction of the abstract results
“In the Results subsection of the Abstract. there are numbers reported which are inconsistent with those of the main text.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TRD cohort had significantly higher total PPPY healthcare costs than the non-TRD MDD cohort ($25,059 vs. $19,945, adjusted cost difference = $3,377) and non-MDD cohort ($25,059 vs. $14,410, adjusted cost difference = $3,675, all P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare beneficiaries aged 65 years or older: resource use, costs, and hospitalization risk
“After matching, 178 patients from each cohort were analyzed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During 12 months of follow-up, TRD patients had higher use of different antidepressants and antipsychotics, higher inpatient and emergency room visits, longer inpatient stays, and higher total healthcare costs ($24,543 versus $16,059, $8,058) than non-TRD MDD and non-MDD cohorts, respectively (all p <0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Risk of initial hospitalization was higher in the TRD (hazard ratio [HR] = 3.60, 95% confidence interval [CI] = 2.08-6.23) and non-TRD MDD cohorts (HR = 1.82, 95% CI = 1.02-3.25) than the non-MDD cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicaid beneficiaries: resource use and costs
“TRD beneficiaries had higher HRU than 1:1 matched non-TRD-MDD (e.g., inpatient visits: IRR = 1.41) and non-MDD beneficiaries (N = 14,710 per cohort; e.g., inpatient visits: IRR = 3.42, p < 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TRD beneficiaries incurred greater costs versus non-TRD-MDD (CD = US$4382) and non-MDD beneficiaries (CD = US$8294; p < 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicaid beneficiaries initiating esketamine, electroconvulsive therapy, or transcranial magnetic stimulation: mental health-related resource use and costs
“ESK cohort included 151 patients (mean age: 40.6 years; female: 70.2%), ECT cohort included 198 patients (mean age: 43.0 years; female: 60.6%), and TMS cohort included 140 patients (mean age: 39.5 years; female: 65.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean MH-related acute care costs during the follow-up period trended lower in ESK cohort (IP: $76; ED: $29) relative to ECT (IP: $1,547; ED: $45) and TMS cohorts (IP: $238; ED: $123).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Outpatient costs in ESK cohort ($1,632) exceeded OP costs in ECT ($1,023) and TMS ($1,051) cohorts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This finding should be interpreted with caution, given potential differences in patient profiles, clinical history and setting of administration.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Veterans Health Administration: resource use and health care costs
“After 1:1 exact matching, 10,449 patients were included in each cohort (mean age: 48.9 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with TRD had higher per patient per year (PPPY) HRU than non-TRD MDD (all-cause inpatient visits: incidence rate ratio [IRR]: 1.70 [95% confidence interval: 1.57-1.83]) and non-MDD (IRR: 5.04 [95% confidence interval: 4.51-5.63]), and incurred higher total all-cause health care costs PPPY than non-TRD MDD (mean difference: $5,906) and non-MDD (mean difference: $11,873; all p<.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental health care and productivity costs across studies: systematic review of United States data, 1996 to 2013
“Annual costs for health care and lost productivity were $5,481 and $4,048 higher, respectively, for patients with treatment-resistant versus treatment-responsive depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At current rates of 12%-20% among all depressed patients, treatment-resistant depression may present an annual added societal cost of $29-$48 billion, pushing up the total societal costs of major depression by as much as $106-$118 billion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs across increasing levels of non-response: systematic review
Inpatient bed-days, outpatient visits, and lost workdays: population-based cohort in Stockholm, Sweden
“Of these, 12 793 episodes (11%) fulfilled criteria for TRD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with matched non-TRD episodes, TRD episodes had more inpatient bed-days (mean, 3.9 days; 95% CI, 3.6-4.1, vs 1.3 days; 95% CI, 1.2-1.4) and more lost workdays (mean, 132.3 days; 95% CI, 129.5-135.1, vs 58.7 days; 95% CI, 56.8-60.6) 12 months after the index date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This cohort study found that, compared with patients with MDD and no TRD episodes, patients with TRD episodes had higher prevalence of psychiatric comorbid conditions, twice the utilization of outpatient health care resources, 3 times the number of inpatient bed-days, and 23% higher all-cause mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care professional visits versus the general population: five European countries
“Additionally, healthcare resource utilization was significantly higher for TRD patients more so than nTRD, compared to the general population, especially for healthcare professional visits (odds ratio nTRD = 5.4; TRD = 15.9, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote